Researchers from the University of Tokyo have found a way to observe clotting activity in blood as it happens — without needing invasive procedures. Using a new type of microscope and artificial intelligence (AI), their study shows how platelet clumping can be tracked in patients with coronary artery disease (CAD), opening the door to safer, more personalized treatment.
If you've ever cut yourself, you’ve seen platelets in action — these tiny blood cells are like emergency repair workers, rushing to plug the damage and stop bleeding. But sometimes, they overreact. In people with heart disease, they can form dangerous clots inside arteries, leading to heart attacks or strokes.
“Platelets play a crucial role in heart disease, especially in CAD, because they are directly involved in forming blood clots,” explained Dr. Kazutoshi Hirose, an assistant professor at the University of Tokyo Hospital and lead author of the study. “To prevent dangerous clots, patients with CAD are often treated with antiplatelet drugs. However, it's still challenging to accurately evaluate how well these drugs are working in each individual, which makes monitoring platelet activity an important goal for both doctors and researchers.”
That challenge pushed Hirose and his collaborators to develop a new system for monitoring platelets in motion, using a high-speed optical device and artificial intelligence.
“We used an advanced device called a frequency-division multiplexed (FDM) microscope, which works like a super high-speed camera that takes sharp pictures of blood cells in flow,” said co-author Yuqi Zhou, an assistant professor of chemistry at the University of Tokyo . “Just like traffic cameras capture every car on the road, our microscope captures thousands of images of blood cells in motion every second. We then use artificial intelligence to analyze those images. The AI can tell whether it’s looking at a single platelet (like one car), a clump of platelets (like a traffic jam), or even a white blood cell tagging along (like a police car caught in the jam).”
The research team applied this technique to blood samples from over 200 patients. Their images revealed that patients with acute coronary syndrome had more platelet aggregates than those with chronic symptoms — supporting the idea that this technology can track clotting risk in real time.
“Part of my scientific curiosity comes from the recent advances in high-speed imaging and artificial intelligence, which have opened up new ways to observe and analyze blood cells in motion,” said Dr. Keisuke Goda, a professor of chemistry at the University of Tokyo who led the research team. “AI can ‘see’ patterns beyond what the human eye can detect.”
One of the most important findings was that a simple blood drawn from the arm — rather than from the heart’s arteries — provided nearly the same information.
“Typically, if doctors want to understand what's happening in the arteries, especially the coronary arteries, they need to do invasive procedures, like inserting a catheter through the wrist or groin to collect blood,” said Hirose. “What we found is that just taking a regular blood sample from a vein in the arm can still provide meaningful information about platelet activity in the arteries. That’s exciting because it makes the process much easier, safer and more convenient.”
The long-term hope is that this technology will help doctors better personalize heart disease treatment.
“Just like some people need more or less of a painkiller depending on their body, we found that people respond differently to antiplatelet drugs. In fact, some patients are affected by recurrent thrombosis and others are suffering from recurrences of bleeding events even on the same antiplatelet medications,” said Hirose. “Our technology can help doctors see how each individual’s platelets are behaving in real time. That means treatments could be adjusted to better match each person’s needs.”
“Our study shows that even something as small as a blood cell can tell a big story about your health,” Zhou added.
###
Journal article:
Kazutoshi Hirose, Satoshi Kodera, Masako Nishikawa, Masataka Sato, Yuqi Zhou, Hongqian Zhang, Shun Minatsuki, Junichi Ishida, Norifumi Takeda, Huidong Wang, Chuiming Kong, Yunjie Deng, Junyu Chen, Chenqi Zhang, Jun Akita, Yuma Ibayashi, Ruoxi Yang, Hiroshi Kanno, Nao Nitta, Takeaki Sugimura, Norihiko Takeda, Makoto Kurano, Yutaka Yatomi, Keisuke Goda, “Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets”, Nature Communications, https://doi.org/10.1038/s41467-025-59664-8
Funding: This work was supported by AMED (JP23hma922009 and JP20wm0325021), JSPS KAKENHI (19H05633, 20H00317, JP21K15640, JP23H02810), JSPS Core-to-Core Program (JPJSCCA20190007), UTOPIA Research Grants for Young Researchers (JP223fa627001), White Rock Foundation, Nakatani Foundation, Charitable Trust Laboratory Medicine Research Foundation of Japan, and KAKETSUKEN.
Useful links:
Graduate School of Science - https://www.s.u-tokyo.ac.jp/en/index.html
Department of Chemistry - https://www.chem.s.u-tokyo.ac.jp/wp/en
Research contact:
Professor Keisuke Goda
Department of Chemistry, The University of Tokyo,
7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
goda@chem.s.u-tokyo.ac.jp
Press contact:
Mr. Rohan Mehra
Public Relations Group, The University of Tokyo,
7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan
press-releases.adm@gs.mail.u-tokyo.ac.jp
About The University of Tokyo:
The University of Tokyo is Japan's leading university and one of the world's top research universities. The vast research output of some 6,000 researchers is published in the world's top journals across the arts and sciences. Our vibrant student body of around 15,000 undergraduate and 15,000 graduate students includes over 4,000 international students. Find out more at www.u-tokyo.ac.jp/en/ or follow us on X (formerly Twitter) at @UTokyo_News_en.
END